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Organ transplantation in older people is increasing, but how aging impacts B-cell
responses to organ transplantation is still unknown. Here, we show that the depletion
of B cells with anti-CD20 antibodies has disparate effects depending on recipient age. In
young murine recipients, anti-CD20 treatment impaired the ability of immune modula-
tion to extend skin allograft survival. In contrast, anti-CD20 treatment extended allograft
survival in aged recipients treated with immune modulation. Although regulatory B-cell
function and the numbers of marginal and follicular B cells were similar between age
groups, a subpopulation of B cells, termed age-associated B cells (ABCs), accumulated
upon aging. ABCs isolated from aged mice exhibited upregulation of CD73, CD80, CD106,
and TLR2 and an increased capacity to augment T-cell alloimmunity compared to ABCs
from young mice. Importantly, ABCs from aged, but not young, mice impaired the ability
of immune modulation to enhance allograft survival after adoptive transfer into young
transplant recipients. Our study indicates that ABCs impair the immune regulation of
allografts. Thus, recipient age needs to be considered when proposing B-cell-depleting
immune therapy.
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Introduction
B cells produce antidonor antibodies against transplant antigens
that enhance acute and chronic rejection [1–3]. B cells also act as
antigen present cells (APCs) to enhance cellular immunity toward
Correspondence: Dr. Daniel R. Goldstein
e-mail: drgoldst@med.umich.edu
an allograft [4, 5]. In addition to these proimmune functions of B
cells, a subpopulation of B cells, termed regulatory B (Breg) cells,
has been identified that promote immune regulation by produc-
ing IL-10 [2, 4, 6–9]. Hence, B-cells play important and diverse
roles that can either enhance or suppress immunity toward organ
allografts.
The most rapid subpopulation of patients seeking organ trans-
plants, including kidney and heart transplants, are over 65 years
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of age [10]. Despite the increasing numbers of older patients
that receive organ allografts, our understanding of how aging
impacts the immune response to organ transplantation remains
unclear. Studies have found that aging impacts T-cell and den-
dritic cell (DC) responses after organ transplantation [11–15].
Yet, the role of aging on B cells following organ transplantation is
unexplored.
In this study, we reveal that recipient age plays a critical role in
the outcome of B-cell depletion following organ transplantation.
We found that, in young (2–4 months of age) murine skin allo-
graft recipients, B-cell depletion via anti-CD20 treatment impairs
the ability of anti-CD45RB and anti-CD154 treatment to maximally
extend graft survival. This observation is consistent with previous
studies in humans that show that anti-CD20 precipitates acute
renal allograft rejection [16]. In sharp contrast, we uncovered
that allografts survived longer in aged recipients (16–18 months
of age) receiving anti-CD45RB and anti-CD154 when the recipi-
ents were also treated with anti-CD20. Upon aging, a subpopula-
tion of nonfollicular, nonmarginal B cells, termed age-associated B
cells (ABCs: CD19+, CD21−, CD23−, CD43−, CD93−), accumulate
and exhibit enhanced activation and increased T-cell alloimmune
priming capabilities. Importantly, adoptive transfer of ABCs iso-
lated from aged mice into young skin allograft recipients impairs
the ability of anti-CD45RB and anti-CD154 to extend allograft
survival. Our findings indicate that, upon aging, heightened T-cell
priming by the B-cell pool may impair the immune regulation of
allografts, which suggests that host age impacts the response to
B-cell immune depletion.
Results and discussion
To determine how aging impacts B-cell responses to organ trans-
plantation, we evaluated how B-cell depletion influenced the
immune regulation of skin allografts in young and aged murine
recipients. We found that B-cell depletion via anti-CD20 anti-
bodies has disparate effects depending on recipient age, findings
that should be taken into consideration when treating aged organ
recipients and recipients with other inflammatory conditions.
Recipient age critically impacts the outcome of
anti-CD20 on the immune regulation of allografts
Anti-CD20 monoclonal antibodies (mAbs) have been used to
deplete B cells and reduce alloantibody levels prior to transplan-
tation [17]. We found that administering 100 μg mAb against
CD20 every 10 days for a total of four serial doses effectively
depleted the splenic B-cell pool (CD19+ cells) in both young
(2–4 months of age) and aged (16–18 months of age) C57BL/6
mice compared to isotype controls (Supporting Information Fig.
1A). Within the B-cell pool, anti-CD20 treatment ablated the fol-
licular (CD19+, CD23hi, CD21mid), the marginal zone B-cell pool
(CD19+, CD23mid, CD21hi) and the CD19+, CD23−, CD21− pop-
ulation in the spleens of both young and aged mice (Supporting
Information Fig. 1B and C). Thus, anti-CD20 effectively ablates
the B-cell pool in both young and aged mice.
We then examined the impact of B cells on the efficacy of anti-
CD45RB, an agent that blocks signal one between APCs and T
cells [18], and anti-CD154, a signal two blocker [19], to maximally
enhance BALB/c skin graft survival in young and aged C57BL/6
mice. Anti-CD45RB and anti-CD154 have been shown to extend
graft survival in murine transplant recipients [18], although aged
recipients do not exhibit the maximal extension of graft survival
observed in young recipients [20]. Treatment with anti-CD45RB
and anti-CD154 reduced the total B-cell pool by 50% seven days
after skin allograft transplantation in both young and aged recip-
ients (Supporting Information Fig. 1D). Additionally, compared
to isotype controls, the B-cell pool remained ablated at 3 weeks
posttransplantation in young and aged mice that received periop-
erative anti-CD45RB, anti-CD154, and a skin allograft with anti-
CD20 mAb (Supporting Information Fig. 1E). These data show
that anti-CD20 mAb is highly effective at ablating B cells in murine
recipients treated with anti-CD45RB and anti-CD154.
In young skin allograft recipients, we found that B-cell deple-
tion with anti-CD20 mAb impaired the ability of anti-CD45RB and
anti-CD154 to maximally extend allograft survival compared to an
isotype control of anti-CD20 (Fig. 1A). (The isotype control did
not impact the efficacy of anti-CD45RB and anti-CD154 to extend
allograft survival; there was no significant difference in graft sur-
vival times between young mice that received anti-CD45RB and
anti-CD154 with the isotype control compared to young mice that
received anti-CD45RB and anti-CD154 without the isotype control
(Fig. 1A)). In contrast, in aged recipients, B-cell depletion led to a
small but significantly enhanced ability of anti-CD45RB and anti-
CD154 to extend allograft survival compared to aged recipients
that received anti-CD45RB, anti-CD154, and an isotype control
of anti-CD20 (Fig. 1B). B-cell depletion alone in aged recipients
did not impact the tempo of skin allograft rejection (Fig. 1B), an
expected finding given the immunogenicity of full major histocom-
patibility complex (MHC) skin graft rejection, which is a T-cell-
dependent process [21]. Thus, these results indicate that recipi-
ent age critically impacts the outcome of B-cell depletion on the
immune regulation of allografts. Specifically, with an immunoreg-
ulatory regimen that exhibits an age-dependent effect on graft sur-
vival [20], B-cell depletion enhances immune regulation in aged
recipients but impairs it in young recipients.
Aging does not alter Breg function
In islet and cardiac allograft models, CD45RB and anti-CD154 are
known to act via Breg cells to enhance graft survival [6, 22].
Thus, an increased potency of Breg function in young recipi-
ents than in aged recipients could explain the different effects
of B-cell depletion observed between young and aged trans-
plant recipients. Production of the immune suppressive cytokine,
IL-10, is a consistent hallmark of Breg function that limits T-cell
immunity [23, 24]. However, we found no difference in the pro-
portion of IL-10-producing B cells upon ex vivo stimulation with
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Figure 1. Recipient age alters the impact of B-cell depletion on the immune regulation of skin allografts. (A) Young C57BL/6 mice received BALB/c
skin transplants with either no further treatment or treatment with anti-CD45RB, anti-CD154, and anti-CD20 mAb or an isotype control to anti-
CD20 mAb. Allograft survival was assessed. p = 0.006: isotype, median survival time (MST) 75 days versus anti-CD20, MST = 25 days (Log-rank). p
< 0.0001: anti-CD45RB, anti-CD154 versus no treatment (MST = 12 days). p = 0.5: isotype control + anti-CD45RB, anti-CD154 versus anti-CD45RB,
anti-CD154 + no isotype control (MST = 86 days). Pooled data from two independent experiments. (B) Aged C57BL/6 mice received BALB/c skin
transplants with either no further treatment, treatment with anti-CD20 only, or treatment with anti-CD45RB, anti-CD154, and anti-CD20 mAb or an
isotype control to anti-CD20 mAb. Allograft survival was assessed. p = 0.05, isotype (MST = 26 days) versus anti-CD20 (MST = 30 days) (Log-rank). p <
0.0001 anti-CD45RB, anti-CD154 versus no treatment (MST = 10 days). Anti-CD20 treatment alone, MST = 8 days. Pooled data from six independent
experiments. (C, D) Aged and young splenic B cells were enriched by magnetic negative separation and stimulated with LPS, PMA, and ionomycin
at the indicated doses (see methods). (C) The proportion of IL-10-producing cells was assessed after intracellular cytokine staining (pooled data
from two independent experiments, n = 12 biological replicates/group). (D) Representative flow cytometric plots gated on B220+ cells are shown. (E)
Spleens of aged and young mice were stained with fluorescent antibodies, and data were acquired via flow cytometry. The percentage of CD19+,
CD1dhi,and CD5+ within total splenic B-cell pool was measured (n = 6 mice/group). The data are pooled from two independent experiments.
(F) Enriched B cells from the spleens of young and aged mice 1 week after skin allograft transplantation and treatment with anti-CD45RB and
anti-CD154. The cells were stimulated with LPS, and IL-10 was measured by ELISA (n = 4 biological replicates/group). Nonactivated cells did not
produce IL-10 (not shown). Data are from a single representative experiment from a total of three independent experiments, each experiment
yield consistent results. (C, E, and F) Data are shown as mean + SEM.
lipopolysaccharide (LPS) in the spleens of young and aged mice
prior to transplantation (Fig. 1C and D). We also found no differ-
ence in the proportion of CD19+, CD1dhi, CD5+, cells that contain
putative Breg populations [7], between the spleens young and
aged mice (Fig. 1E). (Note that IL-35 a marker of IL-10-producing
B cells was not assessed [25]). After mice were transplanted and
treated with anti-CD45RB and anti-CD154, we found no differ-
ence in IL-10 production in the spleens of young and aged mice
(Fig. 1F). Thus, we did not find that Breg function or numbers are
altered upon aging.
Aging increases the accumulation of ABCs that exhibit
immune memory and activation phenotypes
As we did not identify an alteration in Breg number or function
between young and aged mice, we next examined other popu-
lations of B cells, including follicular and marginal zone B cells.
We did not find increases in the total CD19+ B cells pool or in
the subpopulations of follicular or marginal zone B cells between
the spleens of young, aged, and advanced aged (24 months of
age) mice (Fig. 2A). However, we found an increase in a CD19+,
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Figure 2. Aging increases the accumulation of ABCs that exhibit memory and activation phenotypes. (A) The spleens of young (2–4 months of age),
aged (16–18 months of age), and advanced aged mice (22–24 months of age) were harvested and stained with appropriate fluorescent antibodies,
and data were acquired via flow cytometry. Absolute cell number or proportions are shown. *p < 0.01, n = 4–6 mice/group, representative of one
experiment that was repeated two times with consistent results. (B) Enriched splenic B cells from nontransplanted and nontreated young and
aged mice were stained with the indicated fluorescent antibody and gated on the ABC subpopulation. Relative median fluorescence intensity is
normalized to average median fluorescence intensity of young mice. *p < 0.01, (t-test) between young and aged groups, n = 16 mice/group. (C)
Enriched splenic B cells were obtained 12 days after skin allotransplantation and treatment with anti-CD45RB and anti-CD154 in young and aged
recipient mice. Staining is per (B). *p < 0.01, (t-test) n = 6 mice/group. (B, C) Data are shown as mean + SEM and are representative of pooled data from
either four (B) or two (C) independent experiments. (D) Representative flow cytometry plots gated on ABC subpopulation from nontransplanted
mice from B are shown (gating is shown in Supporting Information Fig. 2A). Plots are representative of four independent experiments.
CD23−, CD21−, CD43−, CD93− population of B cells known as
ABCs [26, 27] (Fig. 2 and Supporting Information Fig. 2A). We
found low proportions (<1% BrdU+ cells) of proliferating cells
within the ABC population of both young and aged mice. We
also found similar proportions of apoptotic (Annexin V+) cells
in splenic B-cell subpopulations in young and aged mice (Sup-
porting Information Fig. 2B). These results suggest that neither
differences in cellular proliferation nor the degree of apoptosis
explain the increased numbers of ABCs in the spleens of aged
mice.
We found that ABCs isolated from aged mice exhibited a three-
fold higher proportion of CD73 and CD80 positive cells, markers
of memory B cells [28, 29], as compared to ABCs from young mice
(Fig. 2A and Supporting Information Fig. 2C and D). CD73hi ABCs
also coexpressed CD80 (a memory B-cell marker [29] and costim-
ulatory molecule) with CD73hi ABCs from aged mice exhibiting
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a higher expression of CD80 as compared to CD73hi ABCs from
young mice (Supporting Information Fig. 2E). Additionally, ABCs
isolated from aged mice exhibited a two-fold increase in MHC class
II, and a 10% increase in TLR4 compared to ABCs isolated from
young mice, respectively (Fig. 2B and D). In contrast, within the
follicular and marginal zone B-cell populations, only MHC Class
II expression was higher in the aged B-cell subpopulations com-
pared to the young ones (Supporting Information Fig. 2F). Besides
TLR4, these changes in ABCs persisted after aged and young mice
were transplanted and treated with anti-CD45RB and anti-CD154
(Fig. 2C). These data indicate that ABCs exhibit an increase in
activation and an immune memory phenotype upon aging.
Aging enhances priming of allogeneic T cells in vitro
As ABCs from aged mice exhibited increases in CD80 and MHC
class II, which can enhance priming of T-cell function [30], we
next assessed the alloimmune T-cell priming function of aged and
young B cells. Enriched splenic B cells (total CD19+ population)
from aged C57BL/6 mice exhibited an enhanced ability to induce
both BALB/c CD4+ and CD8+ T-cell proliferation in vitro com-
pared to B cells purified from young C57BL/6 mice (Fig. 3A and
Supporting Information Fig. 3A). Furthermore, splenic B cells that
were enriched from aged transplant recipients treated with anti-
CD45RB and anti-CD154 exhibited an enhanced ability to activate
allogeneic T-cells ex vivo compared to splenic B cells isolated from
similarly treated young mice (Fig. 3B).
We then further purified aged and young splenic B cells into fol-
licular, marginal, and ABC subtypes via fluorescence-activated cell
sorting (FACS; Supporting Information Fig. 3B) and cultured the
purified subpopulations with allogeneic (BALB/c) CD4+ and CD8+
T cells. ABCs, but not marginal or follicular B cells, purified from
the spleens of aged C57BL/6 mice exhibited an age-dependent
enhancement in the ability to induce T-cell alloimmune prolif-
eration (Fig. 3C). ABCs purified from aged mice also increased
IL-2 and IFN-γ production by allogeneic T cells compared to ABCs
purified from young mice, whereas follicular and marginal zone
B cells did not exhibit age-dependent increases in IL-2 and IFN-γ
production (Fig. 3D). IL-17 was detected at low levels in this assay
with no differences noted between the cell populations upon aging
(Supporting Information Fig. 3C). Together, these data show that
ABC exhibit enhanced in vitro T-cell alloimmunity upon aging.
Aged B cells exhibit enhanced IL-2 T-cell alloimmune
responses in vivo
As anti-CD20 mAb ablates all B-cell subpopulations examined
(Supporting Information Fig. 1B), we tested the requirement for
B-cells in anti-donor T-cell priming in vivo. We transplanted aged
C57BL/6 mice with a BALB/c skin graft and administered anti-
CD45RB and anti-CD154 along with the anti-CD20 mAb or an
isotype control of anti-CD20 mAb. We found that, 3 weeks after
transplantation, anti-CD20 treatment reduced IL-2 anti-donor T-
cell responses in aged recipients but not in isotype control-treated
aged recipients (Fig. 3E). In similarly treated young transplant
recipients, anti-CD20 treatment did not alter the anti-donor IL-
2 response (Supporting Information Fig. 3D). These data reveal
that B-cell depletion reduces IL-2 antidonor T-cell responses in
aged skin allograft recipients who receive anti-CD45RB and anti-
CD154.
ABCs isolated from aged mice impair the ability of
anti-CD45RB and anti-CD154 to extend allograft
survival after adoptive transfers into young transplant
recipients
To determine if ABCs from aged, nontransplanted, nontreated
mice were sufficient to impair the immune regulation of allografts,
we adoptively transferred FACS-sorted ABCs from either young
mice or aged CD45.2+ mice into young CD45.1+ mice. Two days
after adoptive transfer, mice were transplanted with a skin allo-
graft and treated with anti-CD45RB and anti-CD154. On the day
of transplantation, we noted that there were between 0.6–0.8% of
CD45.2+ cells in the peripheral blood of recipients. Furthermore,
in a separate cohort of young recipient CD45.1+ mice, the engraft-
ment of adoptively transferred ABCs within the spleen was simi-
lar between transferred ABCs purified from young or aged mice
(0.4–0.6% of splenic ABCs). We found that the transfer of aged,
but not young, ABCs impaired the ability of anti-CD45RB and anti-
CD154 to extend allograft survival in young recipients (Fig. 3F).
At 100 days posttransplantation, aged ABCs remained detectable
(0.76% of spleen cells) within the spleen of the recipients (Fig.
3G). These data provide direct in vivo evidence that ABCs from
aged mice impair the immune regulation of allografts.
Aged transplant recipients exhibit lower alloantibody
levels than young transplant recipients
B cells respond to transplant antigens by producing donor-specific
antibodies (DSAs). Prior to transplantation, we found low and
similar plasma IgG DSA levels between young and aged C57BL/6
mice. Two weeks after BALB/c skin transplantation, both aged and
young mice exhibited increases in the serum levels of anti-donor
IgG alloantibodies; however, the aged recipients exhibited signif-
icantly lower levels than their younger counterparts (Fig. 3H),
which is consistent with previous vaccine studies that show that
aging impairs antibody production [31]. Administration of anti-
CD45RB and anti-CD154 did not impact alloantibody levels, and
the reduced antidonor IgG levels in the aged recipients persisted
(Fig. 3H). These data indicate that aging impairs the production
of DSAs; thus, increased DSA production is unlikely to be a mech-
anism by which aging influences B cells to enhance antidonor
responses.
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Figure 3. Aged B cells enhance anti-donor T-cell immunity and impair the immune regulation of allografts. (A) The total B-cell pool (CD19+ cells)
was enriched by negative magnetic separation from young and aged mice. Cells were irradiated and cultured with allogeneic, (BALB/c), enriched
T cells that were stained with violet proliferation dye. The percentage of dividing cells is from pooled data from three independent experiments
(n = 12–14 biological replicates/age group). *p < 0.01 (t-test). (B) The total B-cell pool (CD19+ cells) was enriched by negative magnetic separation
from young and aged mice 12 days post skin allotransplantation and treatment with anti-CD45RB and anti-CD154. The B cells were irradiated and
cultured with allogeneic T cells ex vivo for 12 h. IL-2 production by T cells was measured via ELISPOT. *p = 0.01 (t-test). N = 7 biological replicates/age
group. T cells that were not stimulated ex vivo produced < 10 spots/105 cells. Data are pooled from two independent experiments. (C) B cells were
FACS sorted into follicular cells, marginal cells, or ABCs (see Supporting Information Fig. 3A for representative FACS plots), irradiated, and cultured
with allogeneic T cells as per A. A representative experiment is shown (n = 3 biological replicates/age group/experiment). *p < 0.01 (t-test).
Consistent results were observed in four independent experiments. (D) MLC culture supernatants from C above were harvested, and IL-2 and
IFN-γ production was measured by ELISA. *p < 0.02 (Mann–Whitney). The data shown are pooled from three independent experiments with three
biological replicates/experiment. (E) Aged C57LB/6 mice were transplanted with BALB/c skin allografts, treated with anti-CD45RB, anti-CD154, and
anti-CD20 mAb or an isotype control. At three weeks posttransplantation, spleens were obtained, and T cells were enriched by magnetic negative
selection and cultured with irradiated donor spleen cells. The number of IL-2-producing T cells was measured via ELISPOT (n = 6 mice/group). *p
= 0.03 (t-test). Data are pooled from two independent experiments. (F) Young CD45.1+ mice received 1 × 106 splenic FACS-purified ABCs via tail
vein injections from young or aged CD45.2+ mice on day −2 relative to skin allograft transplantation. Mice received anti-CD45RB and anti-CD154
as described in section Materials and methods. The difference between the experimental groups was statistically significant, p = 0.0006 (Log-rank).
Data shown are pooled from two independent experiments. (G) ABCs were isolated from aged CD45.2+ mice and transferred into young CD45.1+
mice that were transplanted with a BALB/c skin graft and then treated with anti-CD45RB and anti-CD154. One hundred days after transfer, the
spleens were obtained and the proportion of CD45.2+ cells was determined after appropriate staining and data acquisition via flow cytometry.
Plots are gated on lymphocytes and are representative of a single experiment. (H) Serum was obtained from mice, diluted, and cultured with
allogeneic donor T cells. After the cells were washed, they were stained with an anti-IgG fluorescent antibody, and the data were acquired via flow
cytometry. BL, baseline; Tx, transplantation; Rx, anti-CD45RB + anti-CD154. *p < 0.01. Data are pooled from two independent experiments. (A–E,
H). Data are shown as SEM.
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Concluding remarks
In summary, our study indicates that the accumulation of ABCs,
likely due to a series of environmental exposures, may override the
immunoregulatory functions of B cells in aged transplant recipi-
ents. In addition to these quantitative changes, our work indicates
that upon aging, ABCs also exhibit qualitative changes, such as
an upregulation of costimulatory molecules, which enhances the
priming of allogeneic T cells. However, it is possible that ABCs
directly interact with immunosuppressive cells, such as Breg cells,
to impair immune regulation; this possibility will require future
investigation. The age of the patients is not always stated in clini-
cal studies, such as one reporting that B-cell depletion precipitated
acute allograft rejection [16]. Our study indicates that recipient
age should be considered when investigating the immune response
to B-cell depletion following organ transplantation and possibly in
the treatment of other inflammatory conditions.
Materials and methods
Mice, transplantation, and reagents administered in
vivo
Young (2–4 months), aged (16-18 months), and advanced aged
(22–24 months) C57BL/6 (H2b) mice were obtained from the
National Institutes of Aging rodent colony. Young donor BALB/c
mice (H2d) and C57BL/6 CD45.1+ were purchased from the Jack-
son Laboratory (Bar Harbor, ME, USA).
Full-thickness BALB/c skin was transplanted to the dorsum
of C57BL/6 recipients as described previously [32]. Recipients
were treated with anti-CD45RB (clone HB220, 100 μg intraperi-
toneally on days −1, 0, 1, 2, 5, and 8 relative to transplanta-
tion) and anti-CD154 (clone MR1, 250 μg intraperitoneally on
days 0, 2, 6, and 8 relative to transplantation). Both antibod-
ies were purchased from BioXcell (Lebanon, NH, USA). Complete
loss of the skin graft area was considered as rejection. B-cell deple-
tion was accomplished using an anti-CD20 monoclonal antibody
(four doses of 100 μg/dose administered on days −5, +5, +15,
and +25 relative to transplantation). The anti-CD20 antibody
(clone 5D2) was obtained from Genentech (San Francisco, CA,
USA).
The Yale University Institutional Animal Care and Use Com-
mittee approved the use of animals in this study.
Cell sorting, flow cytometry, adoptive transfer, and
ELISA
The following monoclonal, fluorescently tagged antibodies were
obtained from Biolegend (CD19, TCRβ, CD5, CD21, CD23,
CD43, CD93, CD73, CD40, CD80, CD86, MHC-II, TLR2, TLR4,
B220, CD1b, CD5, TIM-1, and IL-10). Data were acquired on a
BD LSRII flow cytometer and analyzed using FlowJo Software
(TreeStar). For intracellular cytokine staining, 1 × 106 spleen
cells were activated using phorbol 12-myristate 13 acetate (PMA)
(50 ng/mL), ionomycin (500 ng/mL), and LPS (10 μg/mL)
(Sigma) for 4 h as previously described [7]. Golgi stop was added
to the cultures 1 h before staining with the indicated antibodies.
For all flow cytometric analysis, cells were gated on a propid-
ium iodide negative population. Magnetic negative cell enrich-
ment (>95% purity, as assessed by flow cytometric staining) of
splenic B cells (CD19+) and T cells was performed using kits
from Stemcell Technologies (Vancouver, BC, Canada). In spe-
cific cases, B-cell subpopulations (Supporting Information Fig. 3B)
were further sorted by FACS on a BD FACS Aria II cell sorter.
FACS-purified splenic ABCs were transferred at a dose of 1 ×
106 cells/mouse on day −2 relative to transplantation. Enriched B
cells (1 × 106 cells/well) were stimulated with 10 μg/mL LPS for 2
days, and IL-10 (eBioscience, San Diego, CA, USA) concentrations
were measured in the culture supernatants via an enzyme-linked
immunosorbent assay (ELISA). IL-2 (eBioscience) concentrations
were measured in mixed lymphocyte culture (MLC) culture super-
natants via ELISA.
MLC
As described above, B cells were enriched from the spleens of
young or aged C57BL/6 mice and irradiated (1000 RAD). These
cells (2 × 105 cells/well) were then cultured in complete RPMI
media at a ratio of 1:2: B cells:CD4+ or CD8+ T-cells that were
enriched from BALB/c mice. T cells were labeled with violet pro-
liferation dye 450 (BD Biosciences, San Diego, CA, USA) prior
to coculture with irradiated B-cells. Proliferation was assessed at
days 3 and 5 of culture. Prior to flow cytometry cells were stained
with antibodies against TCRβ, CD4, and CD8. Cells were gated
on TCRβ+, CD4+, or TCRβ+ CD8+ and proliferation was deter-
mined by comparing the values to nonactivated (i.e., T cells not
stimulated with B cells) control T cells.
ELISPOT
Recipient T cells (1 × 105 cells/well) and irradiated donor splenic
cells (5 × 105 cells/well) were cultured in 96-well ELISPOT plates
coated with the antibody of interest. After 18 h of culture, the
plates were treated with the reagents according to manufacturer’s
instructions (BD Biosciences). Plates were read on an AID ELISPOT
reader and analyzed using AID ELISPOT software (AID, Strass-
berg, Germany).
Measurement of alloantibodies
Serum was obtained from mice and diluted 1:100 in PBS. The
serum was incubated with enriched allogeneic T cells (target
T-cells; 2 × 105 cells/well) in 96-well plates. After incubating for
1 h at 4ºC, the cells were washed twice with PBS, resuspended, and
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cultured with anti-mouse IgG FITC (Jackson Immuno Research
West Grove, PA, USA) on ice for 30 min. The cells were washed
twice and resuspended in PBS, and then data were acquired on
a flow cytometer. The degree of fluorescence was reported as
median fluorescence intensity as a measure of antidonor antibody
attachment to the target T cells.
Statistics
Means between indicated experimental groups were statistically
analyzed by parametric tests (two-way Student t-test) or nonpara-
metric tests (Mann–Whitney), and survival analyses were per-
formed via a log-rank test using Graphpad Prism Software. A
p-value < 0.05 was considered significant. Error bars shown in
figures represent the standard error of the mean (SEM).
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